

AMENDMENTS TO THE SPECIFICATION

Please replace the third paragraph at page 6, lines 8-21 with the following amended paragraph:

[17] a medicament, which comprises the compound represented by formula (I) depicted in above [1], a salt thereof or a prodrug thereof in combination with one or more of selected from the group consisting of an acetylcholinesterase inhibitor, a nicotinic receptor regulator, a β -secretase inhibitor, a gamma-secretase inhibitor, a β -amyloid protein aggregation inhibitor, a β -amyloid vaccine, a β -amyloid protease, a brain function activator, a cerebral blood flow and metabolism improver, a dopamine receptor agonist, monoamine oxidase inhibitor, an anticholinergic drug, a catechol-o-methyltransferase inhibitor, a curative medicine for amyotrophic lateral sclerosis, a neurotrophic factor, an apoptosis inhibitor, an antidepressant drug, an antianxiety drug, an anticonvulsant drug, an antihypertensive drug, a calcium receptor antagonist, a curative medicine for diabetes, a curative medicine for hyperlipemia, hyperlipidemia, an aldose reductase inhibitor, a nonsteroidal anti-inflammatory drug, a disease-modifying anti-rheumatic drug, an anticytokine drug, a steroid, an antithrombotic drug, a factor Xa inhibitor, a factor VIIa inhibitor, an antioxidant and a glycerite;

Please replace the paragraph bridging pages 38-39 with the following amended paragraph:

As examples of the other drug to be used in the combination drug of the present invention, for example, acetylcholine esterase inhibitors, nicotinic receptor regulators, production, secretion, accumulation, aggregation and/or deposition inhibitors of β -amyloid (e.g., β -secretase inhibitors, gamma-secretase inhibitors, β -amyloid protein aggregation inhibitors, β -

amyloid vaccines, β -amyloid proteases, and the like), brain function activators, improvers of brain circulation and metabolism, other curative medicines of Parkinson's disease (e.g., dopamine receptor agonists, monoamine oxidase (MAO) inhibitors, anticholinergic drugs, catechol-O-methyltransferase (COMT) inhibitors, and the like), curative medicines of amyotrophic lateral sclerosis, neurotrophic factors, curative medicines of abnormal behavior, prowl, and the like accompanied to progression of dementia, apoptosis inhibitor, differentiation/regeneration accelerators of nerve cells, antidepressants, antianxiety drugs, antiepileptic drugs, hypotensive drugs, calcium receptor antagonists, curative medicine of diabetes, curative medicines of hyperlipimeda such as cholesterol-lowering agents (e.g., ~~statines~~statins, fibrates, squalene synthase inhibitors, and the like), aldose reductase inhibitors, nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, anticytokines (e.g., TNF inhibitor, MAP kinase inhibitor, and the like), steroids, sex hormones or derivatives thereof, parathyroid hormone (e.g., PTH), factor Xa inhibitor, factor VIIa inhibitor, antioxidant drugs, glycerites, and the like can be cited.

Please replace the first paragraph at page 41, lines 3-6 with the following amended paragraph:

Examples of ~~statines~~statins of curative medicines of ~~hyperlipimeda~~hyperlipidemia include, for example, pravastatin sodium, atrovastatine, simvastatin, rosuvastatin and the like.

**Please replace the second paragraph at page 41, lines 5-6, with the following
amended paragraph:**

Examples of fibrates of curative medicines of ~~hyperlipimeda~~ hyperlipidemia include, for example, clofibrate and the like.